{"url_path":"/sec/ttrx/8-k/2026-05-18/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 **","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-18","source_url":"https://www.sec.gov/Archives/edgar/data/2023016/0001213900-26-058140-index.html","accession_number":"0001213900-26-058140","cik":"0002023016","ticker":"TTRX","issuer_name":"Turn Therapeutics Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/2023016/0001213900-26-058140-index.html","primary_entity_key":"0002023016","primary_entity_name":"Turn Therapeutics Inc."},"word_count":124,"has_tables":true,"body_markdown":"**Item 7.01**\n**Regulation FD Disclosure.**\n\n \n\nOn May 18, 2026, Turn Therapeutics\nInc. issued a press release (the “Press Release”). A copy of the Press Release is furnished as Exhibit 99.1 to this Current\nReport on Form 8-K.\n\n \n\nThe information in Item 7.01\nof this Current Report on Form 8-K and the Press Release furnished as Exhibit 99.1 hereto shall not be deemed “filed” for\npurposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the\nliabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended,\nor the Exchange Act, except as expressly set forth by specific reference in such a filing."}